首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Immunological medicine

缩写:

ISSN:N/A

e-ISSN:2578-5826

IF/分区:2.3/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引305条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yogi Prawira,Safarina G Malik,Zakiudin Munasir et al. Yogi Prawira et al.
Lipopolysaccharide (LPS)-induced endotoxemia is widely used to model sepsis. This study aimed to identify the LPS dose that reliably induces hyperlactatemia, Murine Sepsis Score (MSS) ≥3 (clinically defined sepsis), dose-dependent differen...
Koichi Saito,Mitsuhiro Akiyama,Kanako Shimanuki et al. Koichi Saito et al.
To perform cross-disease immunological comparison across the broader spondyloarthritis (SpA) spectrum and examine their association with disease activity. We analyzed 111 patients with active broader SpA spectrum (ankylosing spondylitis, in...
Shuhei Yoshida,Kiyoshi Migita,Tomoyuki Asano et al. Shuhei Yoshida et al.
Serious azathioprine (AZA)-related adverse events (AEs) contribute to treatment discontinuation in patients with rheumatic diseases, although real-world data on patient-related risk factors in Japanese patients remain limited. This study in...
Ken Nagahata,Masatoshi Kanda,Yuki Hamakawa et al. Ken Nagahata et al.
IgG4-related retroperitoneal fibrosis (IgG4-related RPF) often causes hydronephrosis requiring ureteral stenting. While glucocorticoid (GC) therapy is generally effective, predictors of successful stent removal remain unestablished. This re...
Taku Inamoto,Hiroyuki Komatsu,Kinya Tsubota et al. Taku Inamoto et al.
Intraocular inflammatory myofibroblastic tumor (IMT) is an extremely rare entity, and its clinical characteristics, immunopathological features, and optimal management remain insufficiently defined. A 57-year-old man presented with visual f...
Takafumi Kadono,Tomomitsu Miyagaki Takafumi Kadono
Immune checkpoint inhibitors, represented by anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-CTLA-4 antibodies, have brought significant therapeutic benefits to many patients with advanced-stage malignancies. By releasing inhibitory si...
Mayuko Kondo,Keisuke Ojiro,Makoto Ueno et al. Mayuko Kondo et al.
Immune-checkpoint inhibitor (ICI)-related cholangitis is a rare but potentially fatal immune-related adverse event. In this study, we retrospectively analyzed 11 patients diagnosed with ICI-related cholangitis between 2020 and 2024 at Keio ...
Sentaro Kusuhara,Koh-Hei Sonoda,Toshikatsu Kaburaki et al. Sentaro Kusuhara et al.
The J-CAT2 study (#jRCT1030240195) aimed to evaluate treatment and patient factors associated with risk of complications/adverse events (AEs) or high corticosteroid exposure in patients with non-infectious uveitis (NIU) using advanced quant...
Koji Suzuki,Hideto Kameda,Kei Ikeda et al. Koji Suzuki et al.
To evaluate the intermediate treatment targets for Still's disease proposed by EULAR/PReS recently, we conducted this post-hoc analysis of the Phase III trial of tocilizumab and its long-term extension to assess the achievement probability ...
Ayaka Kamada,Taichi Nomura,Terufumi Kubo et al. Ayaka Kamada et al.
Immune checkpoint inhibitors (ICIs) can cause severe immune-related adverse events (irAEs), including life-threatening myositis and myocarditis. Characterizing the immunopathological features of these conditions is essential for improving c...